Business Standard

Cipla acquires 4 women's health brands from Wanbury to strengthen segment

Cipla said the nutraceutical products, to be sold under the four umbrella brands, would address various health needs for conditions arising due to nutritional deficiencies or insufficiencies

Cipla, Cipla logo, Cipla headquarters
Premium

Sohini Das Mumbai
Drug major Cipla has acquired the nutrition products portfolio from Mumbai-based Wanbury for an undisclosed sum. 

The acquisition, aimed at strengthening Cipla’s women’s health segment, comprises four brands — CPink, CDense, Productiv, and Folinine. CPink is used to treat anaemia, CDense is used for calcium deficiency, Productiv is used to treat infertility, and Folinine is a folic acid tablet. According to IQVIA (December Moving Annual Turnover), the four molecules have a market size of Rs 3,100 crore in India. At present, these brands clock a sales value of Rs 59.6 crore for Wanbury.

Cipla said the nutraceutical products, to be sold under
Topics : Cipla

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in